Transdermal Drug Delivery

Transdermal delivery of drugs has been around for decades. To date, only small lipophilic molecules such as fentanyl, nicotine and lidocaine have been delivered transdermally. These are potent drugs with therapeutic doses in the microgram range. It is desirable to transdermally deliver many drugs which require frequent intramuscular (IM) or subcutaneous (subcu) delivery by needle injections. The pain and fear of needles has an impact on patient compliance when patients are required to self administer these drugs.

InCube Labs has developed a number of transdermal delivery technologies that can be optimized for specific drugs. Further, with our approach, we can transdermally deliver molecules ranging from a few hundred daltons to greater than 10,000 daltons. For example, we have demonstrated delivery of therapeutic doses of Byetta (Exenatide) and other peptides. With these approaches, drug delivery can be exquisitely controlled ranging from highly localized delivery (little or no systemic exposure) to systemic delivery rivaling intravenous injections or infusions.

Licensees include:

FE3 Medical